Related Experiment Videos
Antitubercular chromones and flavonoids from Pisonia aculeata
Ming-Chun Wu1, Chien-Fang Peng, Ih-Sheng Chen
1Graduate Institute of Natural Products, Department of Biomedical Laboratory Science and Biotechnology, School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan 807, Republic of China.
Journal of Natural Products
|May 6, 2011
Summary
Researchers isolated novel compounds from Pisonia aculeata, with several showing promising antitubercular activity against Mycobacterium tuberculosis. This discovery offers potential new avenues for developing treatments for tuberculosis.
Area of Science:
- Natural Product Chemistry
- Pharmacognosy
- Medicinal Chemistry
Background:
- Pisonia aculeata is a plant species with a history of traditional medicinal use.
- Natural products are a rich source of novel therapeutic agents.
- Tuberculosis remains a significant global health challenge, necessitating the search for new drugs.
Purpose of the Study:
- To isolate and characterize chemical constituents from Pisonia aculeata.
- To evaluate the antitubercular activity of the isolated compounds against Mycobacterium tuberculosis.
Main Methods:
- Phytochemical investigation involving methanol extraction of Pisonia aculeata stem and root.
- Isolation and structural elucidation of compounds using spectroscopic techniques.
- In vitro antitubercular activity screening using Mycobacterium tuberculosis H37Rv.
Main Results:
- Three new chromones (pisonins A, B, D), two new flavonoids (pisonivanone, pisonivanol), one new isoflavonoid (pisonianone), and five other new compounds were identified.
- Eighteen known compounds were also isolated.
- Compounds 2, 7, 14, 16, and 19 demonstrated significant antitubercular activity with minimum inhibitory concentrations (MICs) ≤ 50.0 μg/mL.
Conclusions:
- Pisonia aculeata is a source of diverse and novel chemical entities.
- Several isolated compounds, particularly pisonins, pisonivanone, and pisonivanol, exhibit promising in vitro antitubercular activity.
- Further investigation into these compounds may lead to the development of new anti-tuberculosis drugs.
Related Concept Videos
Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...